Skip to main content
Premium Trial:

Request an Annual Quote

CLC Bio Partners with Ion Torrent to Make Software Compatible with Sequencer


CLC Bio said this week that it is partnering with Ion Torrent Systems to ensure compatibility between Ion Torrent's sequencer and CLC Bio's sequence analysis software.

The company is one of several bioinformatics firms that Ion Torrent is partnering with, which also include DNAStar, Geospiza, and Partek (see In Sequence 3/2/2010).

Under the partnership, CLC Bio and Ion Torrent will ensure that data from the Ion Personal Genome Machine sequencer can directly be analyzed using CLC Bio's software products, including its CLC Genomics Workbench and CLC Genomics Server.

Ion Torrent plans to commercialize its sequencer later this year.

Next month, the company plans to award two Ion PGM sequencers through a grant program (see In Sequence 3/2/2010). CLC Bio said that it will provide a lifetime license for CLC Genomics Workbench to the two winners.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.